Amneal Pharmaceuticals (NASDAQ:AMRX) EVP Sells 210,000 Shares

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) EVP Jason Daly sold 210,000 shares of the stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $17.40, for a total transaction of $3,654,000.00. Following the sale, the executive vice president directly owned 35,171 shares in the company, valued at approximately $611,975.40. This represents a 85.65% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Amneal Pharmaceuticals Price Performance

AMRX traded down $0.39 during midday trading on Thursday, hitting $17.27. The company had a trading volume of 2,244,046 shares, compared to its average volume of 2,168,140. Amneal Pharmaceuticals, Inc. has a twelve month low of $9.15 and a twelve month high of $19.26. The company has a market capitalization of $5.51 billion, a PE ratio of 35.24 and a beta of 1.27. The company has a debt-to-equity ratio of 77.65, a quick ratio of 1.44 and a current ratio of 2.20. The firm’s 50-day simple moving average is $17.08 and its 200-day simple moving average is $14.54.

Institutional Trading of Amneal Pharmaceuticals

Large investors have recently made changes to their positions in the company. Kemnay Advisory Services Inc. bought a new position in Amneal Pharmaceuticals during the fourth quarter worth about $26,000. Federated Hermes Inc. raised its position in shares of Amneal Pharmaceuticals by 1,680.6% during the fourth quarter. Federated Hermes Inc. now owns 2,297 shares of the company’s stock worth $29,000 after purchasing an additional 2,168 shares during the period. Transamerica Financial Advisors LLC raised its position in shares of Amneal Pharmaceuticals by 541.9% during the fourth quarter. Transamerica Financial Advisors LLC now owns 2,914 shares of the company’s stock worth $37,000 after purchasing an additional 2,460 shares during the period. Comerica Bank lifted its holdings in shares of Amneal Pharmaceuticals by 186.7% during the 3rd quarter. Comerica Bank now owns 3,005 shares of the company’s stock valued at $30,000 after purchasing an additional 1,957 shares in the last quarter. Finally, Strs Ohio acquired a new position in shares of Amneal Pharmaceuticals in the 4th quarter valued at approximately $52,000. Institutional investors own 31.82% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on AMRX shares. Weiss Ratings raised Amneal Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, July 29th. Wall Street Zen raised Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, July 12th. Barclays boosted their target price on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 20th. The Goldman Sachs Group reiterated a “buy” rating and issued a $21.00 price target on shares of Amneal Pharmaceuticals in a report on Friday, July 31st. Finally, Zacks Research upgraded Amneal Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating and seven have given a Buy rating to the company. Based on data from MarketBeat.com, Amneal Pharmaceuticals has an average rating of “Buy” and a consensus price target of $17.67.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.